Clinical trials: Diagnostic Imaging Utilization
- Condition Diagnostic Imaging Utilization
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Magnetic Resonance Imaging, Image Enhancement
Drug Use Investigation of Gadovist.
The objectives of this study are to investigate the safety and effectiveness of Gadovist.
- Trial name
- NCT02540967
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- Japan
- Volunteers
- 3,357 people
- Sponsor
- Bayer
Magnetic Resonance Imaging (MRI), Cardiac Pacing
Evaluation of Approved Pacing Lead (Model 5076) for Use in MRI Environment
The purpose of this study is to test the safety and effectiveness of the Medtronic CapSureFix Novus Model 5076 lead when patients are implanted with the Medtronic Advisa MRI pacemaker and undergo an MRI scan.
- Trial name
- NCT01755143
- Testing
- Magnetic Resonance Imaging scan sequences of the head, neck, and chest, Pacemaker System
- Where
- 36 sites in Australia, Austria and 17 more
- Volunteers
- 266 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Diagnostic Imaging
Magnevist Post-marketing Surveillance in Japan
This study is a regulatory post-marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Magnevist at a dose of more than 0.2 ml/kg for MR angiography of peripheral…
- Trial name
- NCT01376739
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- Japan
- Volunteers
- 2,051 people
- Sponsor
- Bayer
Contrast Enhancement in Magnetic Resonance Imaging
A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting
This is an observational study, in which data associated with the wastage with the use of Gadavist single-dose vials, as compared to the wastage associated with the use of the Gadavist imaging bulk packages (IBP) used for…
- Trial name
- NCT05350189
- Testing
- Gadobutrol (Gadavist/Gadovist, BAY86-4875)
- Where
- 2 sites in United States
- Volunteers
- 1,602 people
- Sponsor
- Bayer
Diagnostic Imaging
Primovist Post-marketing Surveillance in Japan
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Primovist for contrast enhancement in MRI of liver.
- Trial name
- PRIMOVIST (NCT01411449)
- Testing
- Gadoxetic Acid Disodium (Primovist, BAY86-4873)
- Where
- Japan
- Volunteers
- 2,030 people
- Sponsor
- Bayer
Magnetic Resonance Imaging (MRI)
Post-marketing Safety Study in Participants of All Pathologies Who Receive Gadolinium-Based Contrast Agents (GBCAs) for Contrast-Enhanced Magnetic Resonance Imaging (MR) Examination
The purpose of this study is to prospectively collect data on the pattern of use for gadolinium-based contrast agents (GBCAs) in real-life setting with special reference to Clariscan after its commercial launch in Europe and in…
- Trial name
- NCT03455283
- Testing
- Clariscan, Gadolinium-Based Contrast Agents
- Where
- 2 sites in Germany, Norway
- Volunteers
- 2,118 people
- Sponsor
- GE Healthcare
Transfusional Iron Overload, Transfusional Hemosiderosis
Evaluating Use of Deferasirox as Compared to Deferoxamine in Treating Cardiac Iron Overload
This is a clinical research study in patients who have iron overload in the heart due to chronic blood transfusions. The study will have 2 treatment groups and will compare the safety and efficacy of chelation therapy with a…
- Trial name
- CORDELIA (NCT00600938)
- Testing
- Core Study: Deferasirox, Core Study: Deferoxamine, Extension: deferoxamine to deferasirox
- Where
- 21 sites in Canada, China and 9 more
- Volunteers
- 197 people
- Sponsor
- Novartis Pharmaceuticals
Kawasaki Disease
A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease
Determine the predictive value of CARDIOLITE® rest and stress myocardial perfusion imaging (MPI) to define a pediatric population with Kawasaki Disease (KD) at high and low risk of developing cardiac events.
- Trial name
- NCT00162032
- Testing
- Sestamibi
- Where
- 50 sites in United States, Brazil and 5 more
- Volunteers
- 445 people
- Sponsor
- Lantheus Medical Imaging
Diagnostic Imaging
PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination
The purpose of this study is to obtain data on the safety and efficacy of Ultravist application in usual daily use.The radiologist will administer the contrast medium to the patient as he/she would have done without the study.
- Trial name
- IMAGE (NCT00876083)
- Testing
- Ultravist (Iopromide, BAY86-4877)
- Where
- 21 sites in Bosnia and Herzegovina, China and 19 more
- Volunteers
- 44,920 people
- Sponsor
- Bayer